Closed · RFA-CA-22-038 · CFDA 93.394;93.395 · Discretionary
Limited Competition: Cancer Immune Monitoring and Analysis Centers (CIMACs) and Cancer Immunologic Data Center (CIDC) (U24 Clinical Trial Not Allowed)
Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.
- Varies
- Award range
- Closed
- Status
- October 24, 2022
- Close date
- -
- Expected awards
The verdict
Limited Competition: Cancer Immune Monitoring and Analysis Centers (CIMACs) and Cancer Immunologic Data Center (CIDC) (U24 Clinical Trial Not Allowed) is a closed discretionary listing from National Institutes of Health that offered Varies by applicant. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.
- Varies
- award range
- Closed
- application status
- 93.394;93.395
- CFDA program
- 12,419
- other opportunities from National Institutes of Health
Archived opportunity record
Limited Competition: Cancer Immune Monitoring… is closed (last close October 24, 2022). Check the agency catalog for replacement NOFOs. National Institutes of Health still indexes 12,419 other opportunities here.
According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.
Deadline tracker
Application window closed
Closed October 24, 2022
Instrument
Cooperative Agreement
Description
Through this limited competition Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications to continue support for the Cancer Immune Monitoring and Analysis Centers Cancer Immunologic Data Center (CIMAC-CIDC) Network. The CIMAC-CIDC is a network of laboratories (CIMACs) and a bioinformatics center (CIDC) established to perform correlative studies using biospecimens from cancer immunotherapy clinical trials. Applying a comprehensive set of state-of-the-art immunoprofiling assays and bioinformatics pipelines, the CIMAC studies encompass genomics, transcriptomics, proteomics, microbiomes, and phenotyping analyses of tumor, tumor microenvironment, blood, stool, and other types of biospecimens. The ultimate goal of the CIMAC-CIDC Network is to identify biomarkers of response, resistance, and adverse events to optimize immunotherapy approaches for patients with cancer. CIMACs work with clinical trial teams and CIDC on correlative studies examining the association of biomarker data from the assays with clinical data from the trials.
Campus applicant desk · Education
Grants.gov prints only higher-education applicant doors for Limited Competition: Cancer Immune Monitoring… (Public / state-controlled institutions of higher education). This reads as a campus competition desk, not a civic or commercial open call. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity codes span Education · Health (ED;HL). Only 173 other National Institutes of Health listings share this exact eligibility-code string (1% of 12,420).
- Code 06
- Public / state-controlled institutions of higher education
Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
NIH OER Webmaster OERWebmaster03@od.nih.gov
More from National Institutes of Health
Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)
Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)
Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
What to do next
Limited Competition: Cancer Immune Monitoring… is closed; use the parent program and agency catalog for the next funding cycle.
- Browse open federal opportunities in the same category when this listing is closed. Open opportunities
- Look up CFDA 93.394;93.395 across all indexed listings before you commit to this opportunity alone. Eligibility finder
- National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog
Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |